News

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

VANCOUVER, BC, April 25, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research Institute (“DRI”) to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatment at Deaconess Health System (“Deaconess”).  DRI, based in […]

BioVaxys Expands Cancer Vaccine Platform

BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND Vancouver, British Columbia, March 30th, 2022 — BioVaxys Technology Corp. (CSE:BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today the expansion of its cancer vaccine platform with BVX-0922, its autologous haptenized tumor vaccine for colorectal cancer (“CRC”).  BioVaxys plans to advance an Investigator-Sponsored Clinical Trial Application (“CTA”) in […]

Biovaxys Announces Complete Inhibition Of ACE-2 Binding Activity of Hapten-Modified SARS-CoV-2 Protein

SUGGESTS SUPERIOR CARDIAC SAFETY COMPARED TO MRNA AND ADENOVIRUS VECTOR VACCINES Vancouver, British Columbia, February 16th, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”) announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor.  The […]

Biovaxys Announces Major Research Collaboration With The Ohio State University To Develop Broadly Reactive Pan-Sarbecovirus Vaccine

VANCOUVER, BC, December 7th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company developing novel approaches to harness T cells to treat cancer and to detect and prevent emerging infectious diseases, announced today that it has entered into a major sponsored research collaboration with The Ohio State University (“Ohio State”) to […]

BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021

VANCOUVER, BC, November 17th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company,  announced today that Company Co-Founder and Chief Medical Officer David Berd, MD, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 taking place November 30-December 2, 2021 in San Diego. Dr. Berd will discuss the […]

BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH

VANCOUVER, BC, November 9th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that results from its in vivo animal research study support the safety and tolerability of CoviDTH at two intradermal dose levels across a battery of clinical pathology, immunology, and histopathology evaluations. The objective of the study was to […]

BioVaxys Further Expands Intellectual Property Portfolio in Global Markets

Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, October 28th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has broadened the patent coverage on CoviDTH, its T cell diagnostic for detecting an immune response to SARS-CoV-2, by filing an international patent application through the […]

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

Vancouver, British Columbia, October 20th, 2021 – BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has filed with the United States Patent & Trademark Office (“USPTO”) a provisional patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses, […]

BioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conference

SARS-Cov-2 spike protein vaccine induced strong antibody and T cell responses in murine model Vancouver, British Columbia, October 8, 2021 – BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that a poster highlighting its preclinical data on BVX-0320, the Company’s SARS-CoV-2 vaccine candidate based on its haptenized viral protein technology, will […]

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission

VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission. Under the terms of a March 2021 agreement, global contract research organization (“CRO”) […]